Navigation Links
Bioengineered Skin Grafts Control Blood Pressure in Mice
Date:1/16/2010

Approach might lead to treatments for other conditions, such as anemia, researchers say

FRIDAY, Jan. 15 (HealthDay News) -- Bioengineered skin cells can produce molecules that control blood pressure in mice, and the same technology is potentially usable against a number of medical conditions, researchers report.

"Our main interest is showing the therapeutic utility of this approach," said Dr. Jonathan Vogel, a senior investigator in the dermatology branch of the U.S. National Cancer Institute, and lead author of the report published online in this week's issue of the Proceedings of the National Academy of Sciences.

Blood pressure control was the target in the mouse experiment because "some of our collaborators on the paper have an interest in hypertension," Vogel said. The study was done in collaboration with researchers at the University of Giessen and Marburg in Germany.

The bioengineered skin cells, which were altered by using a retrovirus to insert a gene into them, were applied as grafts. "Skin grafts are relatively easy to construct," Vogel said. "The desired gene can be placed in the upper part of the skin and also in the fibroblasts, which provide the supportive structure of the skin."

Tests showed that the skin patches lowered the blood pressure of mice fed a normal diet and prevented high blood pressure in mice fed a diet high in salt.

"We used a retrovirus with RNA that makes two proteins," Vogel said. "One of the proteins is a peptide that controls and lowers blood pressure. The other can be used as a marker."

The active molecule produced by the bioengineered cells was atrial natriuretic peptide, a hormone that lowers blood pressure.

The successful trial is just a first step in what promises to be a long road to the use of skin grafts in medicine, Vogel said.

"It is one thing to do it in a mouse," he said. "The question is whether it can be scaled up to use in larger animals. That question still has to be answered."

Other questions are the duration of the effect (because as Vogel noted, "these were fairly short-term studies"), and how many other conditions the technique might be used to treat.

"One other condition we are talking about is anemia," Vogel said. "That has been actively thought of in our laboratory. But that is far in the future. It would require much tighter regulation than we now can achieve."

And while this was "a first step in a small animal model," a point has been proven, he added.

"It shows we can engineer a skin graft, can graft it successfully, and that the product that the skin cells make gets access to the bloodstream, which is not trivial. It gets there in sufficient levels to have a biological effect," Vogel said.

Dorothy Supp, an associate investigator at Shriner's Hospital for Children in Cincinnati and adjunct research professor in the University of Cincinnati's department of surgery, who has her own research project using modified skin cells, called the new study "very exciting."

"My work involves generating modifications in skin cells to improve healing," Supp said. Like Vogel, she uses a retrovirus to modify the cells. "What we would like to do is increase the expression of beneficial genes and decrease the expression of harmful ones," she said.

Skin graft therapy is nearing medical application after 20 years of effort, Supp explained. "The skin is a model system for gene therapy, and the fact that you can put a small graft on an animal and get a systemic response is very exciting," she said.

More information

The U.S. National Library of Medicine has more on skin grafts.



SOURCES: Jonathan Vogel, M.D., senior investigator, dermatology branch, U.S. National Cancer Institute, Bethesda, Md.; Dorothy Supp, Ph.D., associate investigator, Shriner's Hospital for Children, Cincinnati, adjunct research professor, department of surgery, University of Cincinnati; Jan. 11-15, 2010, Proceedings of the National Academy of Sciences, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Reconstructing mandibular defects with bioengineered tooth and bone
2. Bioengineered proteins: Trial confirms new way to tackle cancer
3. Natural aorta grafts have few side effects for infection-prone patients
4. RTI Biologics Sees Expanded Surgeon User Base of Fresh OC Allografts
5. Drug Combo Keeps Kidney Artery-Vein Grafts Viable
6. Reportlinker Adds World Bone Grafts Market Report
7. Bodys own veins provide superior material for aortic grafts
8. Chromatin remodeling complex connected to DNA damage control
9. More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag
10. New Asthma Guidelines Stress Disease Control
11. UI nursing researcher to study post-operative pain control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... ... February 05, 2016 , ... In ... across the country gathered at the La Valencia Hotel in San Diego, California ... Chicago was named the year’s most outstanding franchise, walking away with the coveted ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the ... to wait longer to access the treadmills. It’s a predictable trend. After the excesses ... weight and get in shape by joining gyms, starting new walking or running routines, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the nation’s leading ... Big Game. Take the stress out of your party preparation – follow these easy, ... every stage of the game. , “The key to hosting a successful game-day party ...
(Date:2/5/2016)... ... 2016 , ... At its annual meeting held last week, the American Parkinson ... Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are ... , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016  Montoya Love is recognized by Continental Who,s ... Pharmaceuticals. Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range ... provides healthcare institutions, clinical laboratories and life science researchers ... the globe. ...
(Date:2/4/2016)... Feb. 4, 2016 Frontier Pharma: Chronic ... First-in-Class Innovation Chronic Obstructive Pulmonary ... chronic inflammation of the airways and lungs. Persistent ... make the disease one of the leading causes ... in the world. COPD is linked to cumulative ...
(Date:2/4/2016)... 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... devices to treat life-threatening diseases, today announced results ... December 31, 2015. --> ... forth in our last quarterly call, we strategically ... long-term objective to establish the Aethlon Hemopurifier® as ...
Breaking Medicine Technology: